Successful Completion of the feasibility Studies followed by engagement of nanoComposix to accelerate the development of CoviSafe(TM)
Toronto, Ontario–(Newsfile Corp. – October 21, 2020) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), a progressive medical device technology company, and its co-development partner, Orpheus Medica Inc. (“Orpheus”) are pleased to announce the successful completion of the initial feasibility studies with its polypeptide detection candidates for CoviSafe™.
Therma & Orpheus are also pleased to announce the engagement of nanoComposix Inc. (“nanoComposix”) to complete the development of CoviSafe™. NanoComposix is uniquely positioned to begin final development of CoviSafe™ and to assist Therma & Orpheus with defining optimal reagents and chemistries necessary to make CoviSafe™ an ultrasensitive, rapid, saliva-based, point of care lateral flow test for SARS-CoV-2.
NanoComposix is a global supplier of the widest variety of precisely engineered, highly characterized nanoparticles and provides full-service lateral flow assay development solutions for its medical device customers. nanoComposix has more than a decade of experience building precisely engineered and highly characterized nanomaterials for thousands of customers worldwide.
Therma & Orpheus will retain the commercial rights to the resulting CoviSafe™ rapid saliva test. The companies will work in parallel to complete development of the test prior to clinical testing for submission to Health Canada, FDA and to attain European CE marking to introduce CoviSafe™ into markets as quickly as possible.
Rob Fia, CEO Therma Bright, commented, “We are pleased to complete the feasibility study and advance to next steps in the development of CoviSafe™. It is exciting to work with such a proactive and experienced team at nanoComposix. nanoComposix will assist Therma & Orpheus to fast track the development of CoviSafe™.”
Saied Babaei, CEO of Orpheus, commented, “With the help of nanoComposix, we will be able to accelerate our work and bring this critical test to the market quicker. We are impressed by nanoComposix’s expertise in working with Orpheus’ biological candidates to enhance sensitivity and specificity of the CoviSafe™ rapid test. We feel the addition of this strong technical team will further de-risk and accelerate the regulatory process and clinical validation of our saliva-based rapid test.”